What are the indications for trazodone?

Indications of Trazodone

Trazodone is FDA-approved exclusively for the treatment of major depressive disorder (MDD) in adults 1. However, it has become one of the most widely prescribed medications for off-label uses, particularly insomnia, despite limited evidence supporting these applications.

FDA-Approved Indication

• Major Depressive Disorder (MDD): The only official indication for trazodone is treatment of depression in adults 1
  • Effective antidepressant doses: 150-300 mg daily 2
  • Demonstrates significant reduction in depression severity scores 3

Common Off-Label Uses

Insomnia (Most Frequent Off-Label Use)

Trazodone is the most commonly prescribed medication for insomnia despite lacking FDA approval for this indication 4, 5. This represents a significant disconnect between clinical practice and evidence-based medicine.

• Prescribing patterns: Trazodone became the second most prescribed sleep medication (0.97% of population) after zolpidem, surpassing FDA-approved benzodiazepines 4
• Dosing for sleep: 25-75 mg demonstrates sedative effects 2
• Evidence quality: Guidelines note that physicians increasingly prescribed trazodone "off label" for insomnia "despite the absence of efficacy studies" 4
• Recent data: Meta-analysis shows significant improvement in sleep quality (SMD = -0.827) in depressed patients with insomnia 3

Critical caveat: The widespread use of trazodone for insomnia is driven more by physician concerns about benzodiazepine dependency than by robust efficacy data 4. The 2017 American Academy of Sleep Medicine guideline highlights this practice evolved without supporting evidence.

Anxiety Disorders

Limited evidence suggests potential benefit for anxiety symptoms, particularly when comorbid with depression 6, 7, 5:

• Studies show improvement in anxiety scores associated with MDD
• No clear superiority over other antidepressants for anxiety treatment 6

Other Off-Label Applications

Research suggests potential utility in 7, 5:

• Behavioral disturbances in dementia: Some evidence in neurological populations 8
• Substance use disorders: Benzodiazepine/alcohol dependence
• Sexual dysfunction: May prevent SSRI-induced sexual side effects
• Pain conditions: Fibromyalgia, diabetic neuropathy, chronic pain
• PTSD, OCD, eating disorders: Limited evidence

Important Safety Considerations

Contraindications

• Absolute: Concurrent MAOI use or within 14 days of stopping MAOIs 1

Significant Warnings

• Priapism: Medical emergency requiring immediate discontinuation if erection >4 hours 1
• Orthostatic hypotension and syncope: Particularly relevant in elderly 1
• Increased bleeding risk: Especially with anticoagulants/antiplatelets 1
• Adverse effects more common than comparators: Including somnolence (OR=7.34), sedation (OR=6.53), and blurred vision (OR=17.50) 3
• Serotonin syndrome risk: Particularly with other serotonergic agents 1

Advantages Over Other Antidepressants

• Low risk of sexual dysfunction 2
• Weight-neutral effects 2
• Limited withdrawal symptoms 2

Clinical Decision Algorithm

For depression: Use trazodone as FDA-approved at 150-300 mg daily 1, 2

For insomnia in depressed patients: Consider trazodone 25-75 mg, recognizing improved sleep quality but higher adverse effect burden 2, 3

For insomnia without depression: Recognize this is off-label use with limited supporting evidence despite widespread practice 4. The risk-benefit calculation should account for the lack of robust efficacy data.

Avoid in: Patients taking MAOIs, those with priapism risk factors, untreated narrow-angle glaucoma 1